Treatment Options in Motor Neuron Disease: Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Young Investigators

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug treatment for spinal muscular atrophy types II and III.

  2012cited by this paper
• Creatine for amyotrophic lateral sclerosis/motor neuron disease.

  2012cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2012cited by this paper
• Interventions for latent autoimmune diabetes (LADA) in adults.

  2011cited by this paper
• Drug treatment for spinal muscular atrophy type I.

  2011cited by this paper
• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2011cited by this paper
• TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.

  2010cited by this paper
• ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB.

  2010cited by this paper
• Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice.

  2010cited by this paper
• TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration

  2010cited by this paper
• Muscle-derived stem cells: isolation, characterization, differentiation, and application in cell and gene therapy

  2010cited by this paper
• Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.

  2010cited by this paper
• Exome sequencing reveals VCP mutations as a cause of familial ALS.

  2010cited by this paper
• ALS‐associated fused in sarcoma (FUS) mutations disrupt Transportin‐mediated nuclear import

  2010cited by this paper
• Motor neuron disease: systematic reviews of treatment for ALS and SMA.

  2010cited by this paper
• Association of ALS with head injury, cigarette smoking and APOE genotypes.

  2010cited by this paper
• Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS.

  2010cited by this paper
• Motoneuron transplantation rescues the phenotype of SMARD1 (spinal muscular atrophy with respiratory distress type 1). J Neuroscience 2009; 29: 11761–11771

  2010cited by this paper
• Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

  2009cited by this paper
• Manipulation of Sod1 expression ubiquitously, but not in the nervous system or muscle, impacts age‐related parameters in Drosophila

  2009cited by this paper
• CERVICAL SPINAL CORD THERAPEUTICS DELIVERY: PRECLINICAL SAFETY VALIDATION OF A STABILIZED MICROINJECTION PLATFORM

  2009cited by this paper
• Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis

  2009cited by this paper
• Advances in stem cell research for Amyotrophic Lateral Sclerosis.

  2009cited by this paper
• ALS‐linked P56S‐VAPB, an aggregated loss‐of‐function mutant of VAPB, predisposes motor neurons to ER stress‐related death by inducing aggregation of co‐expressed wild‐type VAPB

  2009cited by this paper
• Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient

  2009cited by this paper
• The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

  2009cited by this paper
• The role of AMPA receptors and VEGF in ALS.

  2009cited by this paper
• The immune boundaries for stem cell based therapies: problems and prospective solutions.

  2009cited by this paper
• Nicotinamide Mononucleotide Adenylyl Transferase-Mediated Axonal Protection Requires Enzymatic Activity But Not Increased Levels of Neuronal Nicotinamide Adenine Dinucleotide

  2009cited by this paper
• Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond

  2009cited by this paper
• Identification of candidate genes for sporadic amyotrophic lateral sclerosis by array comparative genomic hybridization

  2009cited by this paper
• A new subtype of frontotemporal lobar degeneration with FUS pathology.

  2009cited by this paper
• Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6

  2009cited by this paper
• SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis.

  2009cited by this paper
• Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy

  2009cited by this paper
• Drug treatment for spinal muscular atrophy type I.

  2009cited by this paper
• Current hypotheses for the underlying biology of amyotrophic lateral sclerosis

  2009cited by this paper
• WldS requires Nmnat1 enzymatic activity and N16–VCP interactions to suppress Wallerian degeneration

  2009cited by this paper
• The role of AMPA receptors and VEGF in ALS.

  2009cited by this paper
• Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model.

  2009cited by this paper
• Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis.

  2009cited by this paper
• Genetics of motor neuron disorders: new insights into pathogenic mechanisms

  2009influential reference
• ER Stress and Unfolded Protein Response in Amyotrophic Lateral Sclerosis

  2009cited by this paper
• Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice

  2009cited by this paper
• Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.

  2009cited by this paper
• Focal Transplantation-based Astrocyte Replacement is Neuroprotective in a Model of Motor Neuron Disease

  2008cited by this paper
• Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen.

  2008cited by this paper
• T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS

  2008cited by this paper
• Design, power, and interpretation of studies in the standard murine model of ALS

  2008cited by this paper
• Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS.

  2008cited by this paper
• Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice

  2008cited by this paper
• Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy.

  2008cited by this paper
• Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy

  2008cited by this paper
• Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis

  2008cited by this paper
• Gene therapy of amyotrophic lateral sclerosis

  2008cited by this paper
• Analysis of genome-wide copy number variation in Irish and Dutch ALS populations.

  2008cited by this paper
• Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis

  2008cited by this paper
• Tolerance strategies for stem-cell-based therapies

  2008cited by this paper
• Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition

  2008cited by this paper
• VAPB interacts with and modulates the activity of ATF6.

  2008cited by this paper
• TDP‐43 mutation in familial amyotrophic lateral sclerosis

  2008cited by this paper
• Skeletal muscle is a primary target of SOD1G93A-mediated toxicity.

  2008cited by this paper
• Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS

  2008cited by this paper
• ALS drug development: Reflections from the past and a way forward

  2008cited by this paper
• CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS

  2008cited by this paper
• Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.

  2008cited by this paper
• Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.

  2008cited by this paper
• TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

  2008cited by this paper
• Messenger RNA Oxidation Occurs Early in Disease Pathogenesis and Promotes Motor Neuron Degeneration in ALS

  2008cited by this paper
• TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia

  2008cited by this paper
• MHC II gene knockout in tissue engineering may prevent immune rejection of transplants.

  2008cited by this paper
• The effect of hydroxyurea in spinal muscular atrophy cells and patients.

  2008cited by this paper
• Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.

  2008influential reference
• Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

  2008cited by this paper
• Neuron-Specific Expression of Mutant Superoxide Dismutase Is Sufficient to Induce Amyotrophic Lateral Sclerosis in Transgenic Mice

  2008cited by this paper
• ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration

  2008cited by this paper
• Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.

  2007cited by this paper
• Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

  2007cited by this paper
• A genome-wide association study of sporadic ALS in a homogenous Irish population.

  2007cited by this paper
• Respiratory impairment in a mouse model of amyotrophic lateral sclerosis.

  2007cited by this paper
• Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.

  2007cited by this paper
• Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy

  2007cited by this paper
• Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis.

  2007cited by this paper
• Spinal Muscular Atrophy: Classification, Diagnosis, Management, Pathogenesis, and Future Research Directions

  2007influential reference
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cited by this paper
• Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature.

  2007cited by this paper
• GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS

  2007cited by this paper
• TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions.

  2007cited by this paper
• Stem Cells Derived from Human Fetal Membranes Display Multilineage Differentiation Potential

  2007cited by this paper
• Novel therapies for the treatment of cystic fibrosis: new developments in gene and stem cell therapy.

  2007cited by this paper
• Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations

  2007cited by this paper
• Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity

  2007cited by this paper
• Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis

  2006cited by this paper
• Role of Natural Killer Cell Subsets in Cardiac Allograft Rejection

  2006cited by this paper
• Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  2006cited by this paper
• Characterization of Amyotrophic Lateral Sclerosis-linked P56S Mutation of Vesicle-associated Membrane Protein-associated Protein B (VAPB/ALS8)*

  2006cited by this paper
• Recovery from paralysis in adult rats using embryonic stem cells

  2006cited by this paper
• Neuroprotective agents for clinical trials in ALS: systematic assessment.

  2006cited by this paper
• Review ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors

  2006cited by this paper
• Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis.

  2006cited by this paper

• Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates

  2018cites this paper
• Overview and audit of a motor neuron disease ( MND ) consultant ’ s practice against MND Association guidelines : suggestions for earlier diagnosis , provision of treatment , and end-of-life care

  2017cites this paper
• CHARACTERIZATION OF MOLECULAR ISOFORMS AND ROLE OF THE SURVIVAL MOTOR NEURON (SMN) IN MOTOR NEURONS DISEASES

  2014cites this paper